Skip to main content

Table 2 Ongoing studies on PD1 inhibitors and radiation therapy in HNSCC

From: PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report

Abbreviated Trial Name/NCT# Phase Agent(s) Study population Expected Primary Endpoint
NCT01935921 Ib Cetuximab, ipilimumab and IMRT stage III-IVa
HPV+ OPSCC
Dose limiting toxicities (DLT)
RTOG 3504
NCT02764593
III w/phase I lead in Nivolumab and cisplatin CRT stage III-IV, intermediate to high risk HNSCC DLT for phase I
NCT02777385 II Concurrent vs sequential pembro, cisplatin and IMRT stage III-IVb
HNSCC
1 year PFS
1 year failure rate
Acute toxicity rates
HN003
NCT02775812
I Adjuvant pembro, cisplatin and IMRT high risk stage III-IV HSNCC DLT
NCT02641093 II Adjuvant pembro, cisplatin and IMRT high risk stage III-IV HSNCC Treatment related adverse events (TRAE)
Disease free survival (DFS)